Monitoring minimal residual disease (MRD) is an important step in treating cancer patients. You can expand your testing capabilities and improve patient care by relying on Droplet Digital PCR (ddPCR) for MRD results. As part of the Bio-Rad Precision Monitoring portfolio, Bio-Rad’s ddPCR hematology-oncology solutions provide precise and accurate results, without the need for standard curves and extensive interpretation.

Hear how others are using Bio-Rad’s hematology-oncology solutions through testimonials and case studies.